Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Axogen, Inc. - Common Stock
(NQ:
AXGN
)
41.46
-0.46 (-1.10%)
Delayed Quote
Updated: 11:12 AM EDT, Oct 1, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Axogen, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
3 Emerging Biotech Stocks With Significant Upside Potential
↗
September 30, 2026
Delcath Systems, Viking Therapeutics and AxoGen show growth potential backed by analyst Moderate Buy ratings and strong institutional ownership, despite risks like dilution and patent cliffs.
Via
MarketBeat
Topics
Intellectual Property
Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock
September 10, 2026
From
Axogen, Inc.
Via
GlobeNewswire
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
September 10, 2026
From
Axogen, Inc.
Via
GlobeNewswire
Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference
September 01, 2026
From
Axogen, Inc.
Via
GlobeNewswire
Axogen (NASDAQ:AXGN) Shares Slide After Q2 Earnings Miss Overshadows Revenue Beat and Raised Guidance
↗
July 29, 2026
Via
Chartmill
Topics
Earnings
Axogen Inc. (NASDAQ:AXGN) Achieves a Perfect Technical Score and Strong Fundamental Growth
↗
June 20, 2026
Via
Chartmill
Axogen Inc (NASDAQ:AXGN) Rallies on Q1 Revenue Beat and Raised 2026 Guidance
↗
April 28, 2026
Via
Chartmill
Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
August 11, 2026
News Provided by Biotech Insider on behalf of Conexeu Sciences Inc.
From
Biotech Insider
Via
GlobeNewswire
Axogen (AXGN) Q2 2026 Earnings Call Transcript
↗
August 07, 2026
Breast segment revenue surged over 50% year over year, driving accelerated growth.
Via
The Motley Fool
Topics
Earnings
Axogen Inc (NASDAQ:AXGN) Reports Q4 2025 Revenue Growth but Misses Profit Estimates
↗
February 24, 2026
Via
Chartmill
AXOGEN INC (NASDAQ:AXGN) Fits the Minervini Trend Template with Strong Growth Momentum
↗
February 17, 2026
Via
Chartmill
AxoGen Q2 Earnings Call Highlights
↗
July 29, 2026
AxoGen (NASDAQ:AXGN) reported second-quarter 2026 revenue of $69.7 million, up 23.1% from a year earlier, as demand for its Avance nerve graft and broader product portfolio increased across its target...
Via
MarketBeat
Topics
Earnings
Axogen, Inc. Reports Second Quarter 2026 Financial Results
July 29, 2026
Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million
From
Axogen, Inc.
Via
GlobeNewswire
Axogen, Inc. to Report Second Quarter 2026 Financial Results on July 29, 2026
July 15, 2026
From
Axogen, Inc.
Via
GlobeNewswire
The Newest Name on Nasdaq Wants to Help the Body Rebuild Itself
May 22, 2026
From
Energy Metal News
Via
GlobeNewswire
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
↗
May 14, 2026
AxoGen (NASDAQ:AXGN) President and CEO Michael Dale said the company’s growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are...
Via
MarketBeat
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
April 30, 2026
From
TELA Bio, Inc.
Via
GlobeNewswire
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
April 30, 2026
From
Axogen, Inc.
Via
GlobeNewswire
Axogen (AXGN) Q3 2025 Earnings Transcript
↗
April 28, 2026
Axogen (AXGN) Q3 2025 Earnings Transcript
Via
The Motley Fool
Axogen (AXGN) Q1 2025 Earnings Transcript
↗
April 28, 2026
Axogen (AXGN) Q1 2025 Earnings Transcript
Via
The Motley Fool
Axogen, Inc. Reports First Quarter 2026 Financial Results
April 28, 2026
Raises Full Year Revenue Guidance to at Least 20% Growth or $270 million
From
Axogen, Inc.
Via
GlobeNewswire
Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million
↗
April 26, 2026
This healthcare firm develops nerve repair solutions for hospitals and specialists in the U.S. and select global markets.
Via
The Motley Fool
Topics
Regulatory Compliance
Axogen (AXGN) Q2 2025 Earnings Transcript
↗
April 22, 2026
Axogen (AXGN) Q2 2025 Earnings Transcript
Via
The Motley Fool
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
April 14, 2026
From
Axogen, Inc.
Via
GlobeNewswire
Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know
↗
March 24, 2026
This surgical solutions provider for nerve repair reported a notable insider sale amid a year of strong share price gains.
Via
The Motley Fool
Topics
Regulatory Compliance
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
↗
March 21, 2026
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
Axogen (AXGN) Q4 2025 Earnings Call Transcript
↗
February 24, 2026
Axogen (AXGN) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
HighMark Wealth Management Buys 158,855 Shares of Axogen Stock
↗
February 24, 2026
This healthcare firm delivers surgical solutions for peripheral nerve repair, targeting specialized surgeons across U.S. and global markets.
Via
The Motley Fool
Topics
Regulatory Compliance
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
February 24, 2026
From
Axogen, Inc.
Via
GlobeNewswire
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
February 17, 2026
From
Axogen, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
